Jubilant Organosys' Bangalore based subsidiary Jubilant Biosys Ltd, has entered into a drug discovery partnership with BioLeap, LLC, USA.
Under this partnership BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform. The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to IND (Investigational New Drug) candidate selection, for multiple therapeutic areas.
Commenting on the development, Mosur, CEO & president, Jubilant Biosys, said: "We are very pleased to partner with BioLeap to offer the pharmaceutical industry our combined 'best in class' preclinical drug discovery capabilities."
Gerald Evans, chief business officer of BioLeap, added, "We are delighted to have the opportunity to offer our partners the combined capabilities of Jubilant and BioLeap. This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development with BioLeap's leading edge computational fragment-based design capabilities, to deliver high quality, cost-effective pre-clinical drug discovery services".
BioLeap's platform technology is completely "in-silico", and it quickly predicts binding information providing drug designers new insights to efficiently create novel molecules and/or improve existing molecules without the limitations of library screening, thereby reducing the time and cost of traditional screening methods.
Many current screening programmes have hit barriers with regards to finding small molecule candidates for viable validated targets because of limitations in chemical diversity. BioLeap's technology provides a viable solution to this current paradigm. The combined strengths of JBL/BioLeap partnership would be most attractive to companies engaged in rational drug design in therapeutic areas where structural biology plays a key role, which includes but is not limited to any of the top twenty pharmaceutical companies working on anti-infectives, oncology, CNS and other therapeutic areas.